Lb Pharmaceuticals (LBRX) Operating Leases (2024 - 2026)

Lb Pharmaceuticals' Operating Leases history runs 3 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $2.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.8 million, down 11.72% from the prior year.
• Operating Leases retreated to $2.7 million in Q1 2026 per LBRX's latest filing, from $2.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $3.2 million in Q4 2024 and bottomed at $2.7 million in Q1 2026.
• The 3-year median for Operating Leases is $2.9 million (2025), against an average of $2.9 million.
• Biggest YoY gain for Operating Leases was 11.72% in 2025; the steepest drop was 11.72% in 2025.
• Year by year, Operating Leases stood at $3.2 million in 2024, then fell by 11.72% to $2.8 million in 2025, then fell by 3.49% to $2.7 million in 2026.
• Per Business Quant, the three latest LBRX Operating Leases figures stand at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.9 million (Q3 2025).